by Manisha Kashyap, PhD
A recent study published July 23, 2024 in Scientific Reports by researchers from the Tabriz University of Medical Sciences in Iran presents a promising new approach to breast cancer therapy. This innovative method uses ultrasound-assisted encapsulation of folic acid-based carbon quantum dots within breast cancer cell-derived exosomes, potentially transforming the precision and efficacy of cancer treatment.
Challenges in Current Cancer Treatments
Breast cancer remains a leading cause of cancer-related deaths among women worldwide. Despite advancements in treatment, current methods often lack specificity, causing significant toxic side effects.
Traditional chemotherapy drugs, such as methotrexate (MTX), are known for their nonspecific action, harming both cancerous and healthy cells. This not only diminishes treatment effectiveness, but also leads to severe side effects like liver toxicity, nausea, and bone marrow suppression.
The Ex@MTX-CQDs Approach
To tackle these issues, the research team led by Fahimeh Kazeminava and Mohammad Nouri has developed a novel drug delivery system that combines the advantages of exosomes and carbon quantum dots (CQDs). The system, called Ex@MTX-CQDs, involves loading methotrexate within folic acid-derived CQDs, which are then encapsulated within exosomes isolated from breast cancer cells.
Targeted Delivery and Controlled Release
The study emphasizes the system’s dual targeting capability through folate and heparan sulfate proteoglycan receptors, which are abundant on the surface of cancer cells. This targeting mechanism ensures that the drug is primarily delivered to cancer cells, sparing healthy tissues. Additionally, the encapsulation within exosomes helps maintain the drug’s stability and facilitates a controlled release.
The research demonstrated that under normal physiological conditions, the release of methotrexate was minimal (less than 10%). However, when the conditions simulated the tumor microenvironment, the release rate significantly increased to approximately 65%, ensuring that the drug is effectively released at the tumor site.
Improved Efficacy and Reduced Side Effects
Toxicological assessments showed that Ex@MTX-CQDs significantly enhance the delivery efficacy of methotrexate directly to cancer cells. This process increases the disruption of the mitochondrial membrane potential in cancer cells, triggering apoptosis and leading to the cells’ destruction. The study also confirmed the nanocarrier’s stability and its ability to retain the functional properties of the encapsulating exosomes.
Broader Implications
This innovative approach could revolutionize the treatment of breast cancer and potentially other types of cancer with high folate receptor expression. The use of biologically derived nanocarriers for targeted drug delivery represents a significant advancement in nanomedicine, with the potential to reduce the side effects associated with conventional chemotherapy and improve patient outcomes.
Future Directions
The findings from this study pave the way for further research and clinical trials to validate the safety and efficacy of Ex@MTX-CQDs in humans. If successful, this method could become a key component in the fight against breast cancer, offering a more effective and less toxic treatment option for patients worldwide.
Funding and Acknowledgments
This research was supported by the Drug Applied Research Center and the Stem Cell Research Center at Tabriz University of Medical Sciences, as well as the Iran National Science Foundation. The authors extend their gratitude to these institutions for their financial and technical support.
Conclusion
The development of Ex@MTX-CQDs represents a notable advancement in targeted cancer therapy. By leveraging the unique properties of exosomes and carbon quantum dots, this approach offers a promising solution to the challenges of nonspecific drug delivery and associated toxic side effects in breast cancer treatment.
Reference
Kazeminava, F., et al. (2024). Ultrasound-Assisted Encapsulating Folic Acid-Based Carbon Quantum Dots Within Breast Cancer Cell-Derived Exosomes As a Co-Receptors-Mediated Anticancer Nanocarrier for Enhanced Breast Cancer Therapy. Scientific Reports, 14, 16941. The open-access article was published on July 23, 2024. DOI: 10.1038/s41598-024-67934-6
About the Writer:
Dr. Manisha Kashyap (Dr. MK)
BDS (Hons), MSc, PhD (Healthcare)
Manisha Kashyap earned a BS in Dentistry (Gold Medalist) and an MS in Clinical Research, and she is a driven PhD scholar in Health Policy and Management.
With a rich background as a Drug Safety Analyst for top-tier bio pharmaceutical companies, she blends clinical expertise with a passion for advancing healthcare accessibility and innovation through her writing career for the love of science and technology via MedKnow Research Writing Solutions.
Dr. Kashyap’s PhD thesis is on “Artificial Intelligence (AI) and Public Health: Harnessing the Power of AI for Enhanced Public Health Policy and Management.”